Summary The biochemical basis of multidrug-resistant (MDR) phenotype has been investigated in drugresistant sublines independently obtained in our laboratories by single step doxorubicin (DOX) selection of LoVo, DLD1, and SW948 human colon carcinoma (HCC) cell lines. All the chemoresistant sublines have been found to be cross-resistant to DOX, actinomycin-D (ACT-D) and vincristine (VCR) but not to cis-diamminedichloroplatinum (CDDP), and have exhibited an increased expression level of mdrl mRNA and gpl70 glycoprotein. Comparative analyses in drug-resistant and sensitive cells of resistance index, extracellular and intracellular equitoxic DOX concentrations, and mdrl gene products expression have indicated that MDR phenotype is a multifactorial phenomenon due to different and possibly independent biochemical mechanisms which cooperate, in varying degrees from cell line to cell line, in conferring cellular chemoresistance.
In vitro derived drug-resistant cell lines frequently show a typical wide spectrum of chemoresistance to many structurally and functionally unrelated drugs Kaye, 1988) . The multidrug-resistant (MDR) phenotype in human cells is thought to be primarily consequent upon the increased expression of the mdrl gene (Riordan et al., 1985; Shen et al., 1986; Chin et al., 1989) which encodes for a plasma transmembrane glycoprotein of 170 kD (gp 170) Chen et al., 1986) . gpl7O causes reduced intracellular drug accumulation through an energydependent active drug efflux (Dano, 1973; Skovsgaard, 1978) . Recent studies, however, have reported that biochemical phenomena, unrelated to increase in gpl7O expression and/or function, also contribute in conferring the MDR phenotype (Goldenberg et al., 1986; Slovak et al., 1988; Ferguson et al., 1988; Cole et al., 1989; Reeve et al., 1989; Toffoli et al., 1989a) .
In order to define the molecular basis of the MDR phenotype in human colon carcinoma (HCC) cells, we Bristol, Latina, Italy] were sterilely dissolved in saline just before use. '4C-doxorubicin ('4C-DOX) (specific activity 55mCimmol-'); D-1-_4C mannitol (specific activity 59 mCi mmol ') and 3H20 (specific activity 5 mCi ml-') were purchased from Amersham (Buckinghamshire, UK). Cytotoxicity tests Cytotoxic effects of pharmacological treatments were determined by clonogenic assay in liquid medium after about 10 days from drug exposure as described (Lorico et al., 1988) . No significant variations were noted for plating efficiencies in monolayer culture between untreated sensitive parent and drug-resistant cells. Experimental data obtained by clonogenic assay were also confirmed by the trypan blue dye exclusion test, 72 h from cell treatment.
Cell lines
Drug cytotoxicity was calculated as a percentage of cell survival in drug-treated cultures compared to that in untreated controls. Results are reported as drug concentration inhibiting cell growth of 50% (IC50). IC50 was extrapolated by linear regression of experimental data.
Selection of drug-resistant cell mutants Drug-resistant sublines were obtained by treating exponentially growing cell cultures in continuous with 100ngml1' DOX as described (Grandi et al., 1986) . The medium was replaced twice a week with fresh medium containing 100 ng ml1' DOX. After 5-10 weeks, single colonies of drugresistant mutants were harvested with 0.25% trypsin/0.02% EDTA and singularly cultured for more than 12 months in the continuous presence of 100 ng ml-' DOX. Drug-resistant sublines were maintained in presence of 100 ng ml' DOX until at least 24 h before the experiments.
Northern and Southern analyses Total cellular RNA and high molecular weight DNA were extracted from exponentially growing cells by the guanidine chloride method (Cox, 1968) and the proteinase/phenolchloroform method (Maniatis et al., 1982) , respectively.
For Northern blots, RNAs were fractionated by electrophoresis in a denaturing 1% agarose/6% formaldehyde gel and transferred to Gene Screen Plus membrane (New England Nuclear, Florence, Italy) by electroblotting in 0.025 M phosphate buffer pH 6.5 (10 Volts overnight and 40 Volts for 1 h). For Southern blot analysis, 10 jLg of DNA were digested with the EcoRI restriction endonucleases, electrophoresed in agarose gel and blotted onto a Gene Screen Plus membrane as described (Southern, 1975) .
Filters were prehybridised, hybridised and washed as de-scribed (Toffoli et al., 1989b) (Merkel et al., 1989 ), a human P-actin fragment (0.7 kb) derived from BamHI-EcoRI digested plasmid pHFPA-3'UT (Ponte et al., 1983 Cells size was determined using 3H20 and D-1-'4C mannitol as described (Long & Stringfellow, 1988 
Cell line
;Iuu I Cytofluorimetric analyses showed that the increased mdrl mRNA expression levels observed in drug-resistant sublines were associated with a concomitant increase in gpl70 expression (Figure 2 ).
Transmembrane drug equilibria and intracellular equitoxic drug concentrations Parent-cell lines and drug-resistant sublines were analysed for transmembrane DOX equilibria to ascertain whether the enhanced mdrl gene expression in the MDR sublines might completely explain their increased drug resistance. Analyses were performed on 2, randomly chosen, MDR sublines for each parent-cell line: LoVo-R-l and LoVo-R-2, DLDI-R-6 and DLDI-R-8, SW948-R-5 and SW948-R-6. Intracellular DOX accumulation was determined after 1.5 h of continuous cell exposure to the drug, at which time the steady-state in transmembrane drug equilibria was completely established (data not shown).
As shown in Figure 3 , after exposure to the same extracellular DOX concentrations, the corresponding intracellular drug concentrations were very similar within the 3 parent-cell lines and SW948-R sublines. On the contrary, DOX accumulations decreased by about 50-60% in DLD1-R and 60-70% in LoVo-R sublines, as compared to the parent cells.
To determine whether the MDR phenotype in drug-resistant sublines is consequent upon increased intracellular resistance to the drug, the intracellular DOX concentration causing a 50% inhibition of cell growth (ICSOint DOX) was established. The three parent-cell lines, that had a similar chemosensitivity to extracellular DOX concentrations (Table  I) , displayed also a similar intracellular sensitivity to the drug (Table III) . In contrast, although the extracellular drug concentrations inhibiting cell growth of 50% (IC50ext DOX) were different among the three subsets MDR sublines, their respective ICSOint DOX were similar. All MDR sublines exhibited, in fact, an ICSOint DOX about 3.5 times greater than the ICSOint DOX of parent-cell lines (Table III) . Therefore the intracellular drug resistance of the three groups of MDR sublines increased uniformly, in spite of different mdrl mRNA expression levels exhibited. This property was also confirmed in a wide range of intracellular drug concentrations (Figure 4 ). Efflux kinetic analyses performed on drug-sensitive parentcell lines and drug-resistant sublines indicated that decreases of intracellular DOX accumulation in DLDl-R and LoVo-R sublines were consequent upon an increased drug efflux ( Figure 5 ). Since the metabolic inhibitor Na azide eliminated the differences in transmembrane drug equilibria observed (data not shown), it is assumed that drug efflux was due to an energy-dependent biochemical mechanism. No significant differences in DOX efflux were observed among SW948, DLDI and LoVo drug-sensitive and SW948-R drug-resistant cell lines.
Discussion
The present study has indicated that MDR phenotype, at least in the HCC cell lines studied, is a multifactorial phenomenon determined by different and possibly independent biochemical mechanisms which cooperate, in amounts varying from cell line to cell line, in conferring cellular chemoresistance. The analyses on transmembrane DOX equilibria Reeve et al. (1989) which also indicated that at least two different biochemical phenomena lead to MDR. The first one involves gp170 whereas the second is not at present identifiable at molecular level. Possibly, this second drug-resistance mechanism is the only active one in SW948-R sublines. Two gene systems are presently thought to be related to intracellular drug resistance: topoisomerases (Pommier et al., 1986 ) and glutathione-S-transferase (Kano et al., 1987) . These cellular enzymes are involved in DNA conformational modification and cellular detoxification, respectively. The peculiar pattern of cross resistance presented by SW948-R sublines may be useful in elucidating which of these gene systems, if any, is implicated in the intracellular drug-resistance mechanism.
Finally, in all drug-resistant sublines analysed, each drugresistance mechanism increased its effect, as compared to the parent cell line, by a specific and constant factor. In fact, mdrl gene expression level increased about 10 times and the intracellular drug resistance about 3.5 times. At present, we do not know the molecular basis of such a phenomenon, however the constancy of the factorial occurrence looks very promising and deserving of further studies.
